Drugs / HCP1803-3
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05723549 | Feb → Mar 2023 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04959305 | Apr 2021 → Feb 2022 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07660796 | Jul 2026 → Oct 2027 expected | essential hypertension | Hanmi Pharmaceutical Company Limited | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05362110 | May 2022 → Jun 2023 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCP1803-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04959305 ↗ |
| Route | Oral | “Take HCP1803-3 once daily for 2 weeks orally” NCT07660796 ↗ |